Adverse reactions associated with long-term drug administration in Mycobacterium avium complex lung disease

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
Y KamiiK Ohta

Abstract

The number of patients with non-tuberculous mycobacterial lung disease (NTM-LD) worldwide has been increasing. Mycobacterium avium complex lung disease (MAC-LD) accounts for 90% of NTM-LD. MAC-LD necessitates long-term treatment, but adverse reactions with long-term administration of drugs are poorly understood. To evaluate adverse reactions with long-term administration of drugs for MAC-LD. We conducted a retrospective single-centre medical chart review of 364 patients administered two or more drugs between July 2010 and June 2015. The prevalence and median time to onset of adverse reactions were as follows: hepatotoxicity 19.5%, 55 days; leucocytopaenia 20.0%, 41 days; thrombocytopaenia 28.6%, 61.5 days; cutaneous reactions 9.3%, 30 days; ocular toxicity 7.7%, 278 days; and increase in serum creatinine 12.4%, 430.5 days. Multivariate analysis showed that rifampicin use was independently associated with thrombocytopaenia, and ethambutol use was independently associated with increases in serum creatinine. The main adverse reactions appeared within 3 months after start of treatment. Most patients were able to continue treatment with liver-supporting therapy, antihistamine agents or desensitisation therapy; however, ocular toxici...Continue Reading

Citations

Sep 11, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jakko van IngenJae-Joon Yim
May 27, 2021·Journal of Clinical Tuberculosis and Other Mycobacterial Diseases·Kelly M PenningtonZelalem Temesgen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

American Journal of Respiratory and Critical Care Medicine
David E Griffith, Kevin L Winthrop
Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
C Hernández PratsA Pampliega Pérez
American Journal of Respiratory and Critical Care Medicine
Makoto HayashiYutaka Sugita
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
C-C ShuTAMI Group
© 2021 Meta ULC. All rights reserved